Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Guangdong General Hospital, Guangdong Academy of Medical Sciences, Shanghai Pulmonary Hospital, Xiangya Hospital Central South University, Central South University, Shanghai Jiao Tong University, Shanghai Chest Hospital, Kunming Medical University, First Hospital of Jilin University, Jilin University, Sichuan University, West China Hospital of Sichuan University, Linyi People's Hospital, Konkuk University Medical Center, Boehringer Ingelheim (United Kingdom), Boehringer Ingelheim (South Korea), Boehringer Ingelheim (China), Prince of Songkla University